Caribou Biosciences discloses restructuring, strategic review as of Q3 2026 results

Caribou Biosciences reported third quarter 2026 financial results on November 5, 2026. The update follows an October 6, 2026 disclosure in which the company said its board had approved a restructuring tied to a review of strategic alternatives aimed at maximizing stockholder value, a process the company said may include, but are not limited to, a merger, acquisition, business combination, or other strategic transactions involving the company and/or its assets, including dissolution and liquidation.¹

As part of that restructuring, Caribou plans to discontinue its clinical trials and further development activities for vispa-cel and CB-011, along with a substantial reduction in workforce and other cost reduction measures.¹ The board cited the current financing environment for allogeneic CAR-T cell therapies, which has made it increasingly challenging to secure the capital necessary to responsibly advance vispa-cel and CB-011.¹ Caribou said it has not set a timeline for completing the strategic review and does not plan further updates unless the board approves a course of action, the process concludes, or disclosure becomes otherwise appropriate or required.¹

Before the announcement, vispa-cel (also known by its full name vispacabtagene regedleucel, formerly CB-010) was an allogeneic anti-CD19 CAR-T therapy being tested in relapsed or refractory B-cell non-Hodgkin lymphoma, and was described as pivotal trial-ready, with FDA alignment already reached on the phase 3 clinical trial design.¹ CB-011, an allogeneic anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma, had produced clinical data from its CaMMouflage phase 1 trial that the company said demonstrated the potential for deep, durable responses.¹

On the balance sheet, the company held $94.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026, down from $142.8 million at the end of 2025.¹ Caribou reported a GAAP net loss of $26.6 million, or $0.25 per share, for the quarter, compared to a $27.5 million loss, or $0.30 per share, a year earlier.¹